Emcure Pharmaceuticals Limited — Q4 FY25 earnings call

Call held 22 May 2025

Management summary

Emcure Pharmaceuticals delivered strong Q4 and full-year FY25 results, driven by robust domestic and international growth. The company successfully integrated Sanofi's cardio business, expanded its presence in Canada with Mantra, and launched strategic products in derma and women's health. Management provided optimistic guidance for FY26, emphasizing execution, margin expansion, and a target to become debt-free by year-end.

Highlights

  • Q4 FY25 Revenue grew 19.5% YoY to INR 2,116 crores.

  • Full Year FY25 Revenue grew 19% YoY to INR 7,896 crores.

  • Q4 FY25 Domestic business grew 25% YoY to INR 929 crores.

  • Full Year FY25 PAT grew 34.1% YoY to INR 707 crores.

  • Q4 FY25 EBITDA (excl. other income) grew 25.2% YoY to INR 390 crores, with margins at 18.4%.

  • Net debt significantly reduced to INR 488 crores from INR 1,558 crores in FY24.

  • Guidance for FY26 includes 13-14% top line growth and 150 bps margin improvement.

  • Dividend of INR 3 per share recommended for FY25.

Key financials

4 periods

Q4 FY25

  • Revenue
    ₹2,116 Cr
    YoY +19.5%
  • EBITDA Margin
    18.4%
  • PAT
    ₹197 Cr
    YoY +63%
  • Gross Margin
    57.8%

Q4 FY25, excl. other income

  • EBITDA
    ₹390 Cr
    YoY +25.2%

FY25

  • Revenue
    ₹7,896 Cr
    YoY +19%
  • Gross Margin
    60.1%
  • PAT
    ₹707 Cr
    YoY +34.1%
  • Effective Tax Rate
    27%

FY25, excl. other income

  • EBITDA
    ₹1,469 Cr
    YoY +19.4%

What they filed

Q1 FY27: revenue up 32.3%, net profit up 62.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,105 1,029 1,278 1,097 1,261 +14%1,418 +38%1,468 +15%1,451 +32%
EBITDA158 124 245 228 225 +42%300 +142%372 +52%340 +49%
Net profit87 50 140 123 118 +36%259 +418%234 +67%200 +63%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
International Business (FY25) ₹4,236 Cr 27.4%
Domestic Business (FY25) ₹3,660 Cr 23.7%
ROW (FY25) ₹1,510 Cr 9.8%
Europe (FY25) ₹1,474 Cr 9.5%
Canada (FY25) ₹1,252 Cr 8.1%
International Business (Q4 FY25) ₹1,187 Cr 7.7%
Domestic Business (Q4 FY25) ₹929 Cr 6.0%
ROW (Q4 FY25) ₹481 Cr 3.1%
Europe (Q4 FY25) ₹396 Cr 2.6%
Canada (Q4 FY25) ₹310 Cr 2.0%

Capital allocation

high confidence
  • Capex ₹350 Cr
    Yes. I think we've historically guided to probably in the range of about INR 350 crores. And I think we'll be somewhere in that range, give or take, INR 25-50 crores.
  • Debt Net ₹488 Cr
    On the balance sheet side, net debt was reduced to INR 488 crores, a significant improvement from INR 1,558 crores in FY '24.
  • Dividend ₹3/share (final)
    The Board has recommended a dividend of INR 3 per share.
  • M&A Sanofi cardio business Acquisition · Integrated

    Successfully integrated into portfolio, restructuring complete, driving growth.

    FY25 sales INR 440-450 crores, impacted by product shortages. Restructuring efforts expected to drive growth in FY26.

    In the domestic market, we successfully integrated the Sanofi cardio business into our portfolio... So, yes, I think this year, Sanofi sales would have been about INR 440 crores to INR 450 crores. And there was also impact what we had is because there were a few products which are in shortages.
  • M&A Mantra subsidiary Acquisition · Integrated

    Successfully integrated, expanded presence in Canada.

    Contributed to Canada's 35% growth in FY25.

    In international markets, we successfully expanded our presence in Canada with integration of Mantra subsidiary... As far as Canada is concerned, it continues to outperform. In FY '25, the growth was 35%, including full year Mantra performance.
  • M&A Manx Healthcare's portfolio Acquisition · Closed

    Expanded product range and basket of products in U.K., strong pipeline.

    Sales close to USD 15 million to begin with, portfolio of ~100 molecules, good EBITDA margins expected.

    We also acquired Manx Healthcare's portfolio. This will help us to expand our product range, basket of products that we offer in U.K. and will give us a very strong pipeline going forward... Yes. So, we're expecting this year to have sales close to USD 15 million to begin with. And we have a portfolio of about 100 molecules which we have acquired.

Guidance & targets

Revenue

  • Top line growth Revenue · FY26 · High confidence 13% to 14%
    We expect to see top line growth of 13% to 14% in FY '26 with around 150 bps margin improvement, which will happen over the course of the year.

    — Satish Mehta, MD & CEO

  • Domestic business growth Revenue · FY26 · Medium confidence 200 basis points higher than industry (low double digits)
    So, I think for what we'll be looking at, the domestic, the target is to grow 200 basis points higher than the industry. So that will be about your low double digits type of growth.

    — Piyush Nahar, EVP, Corporate Development and Strategy

  • International business growth Revenue · FY26 · Medium confidence mid-teens type of growth
    I think international is where we are expecting more around a mid-teens type of growth.

    — Piyush Nahar, EVP, Corporate Development and Strategy

  • Europe growth Revenue · FY26 · Medium confidence high single digits
    So, I think Europe, what we'll be targeting is on the high single digits.

    — Piyush Nahar, EVP, Corporate Development and Strategy

  • Canada growth Revenue · FY26 · Medium confidence teens level
    Canada, as I said, we continue to aspire to grow in teens level.

    — Piyush Nahar, EVP, Corporate Development and Strategy

  • Emerging markets growth Revenue · FY26 · Medium confidence closer to 20% odd
    Emerging markets is where we see the substantial growth of closer to 20% odd.

    — Piyush Nahar, EVP, Corporate Development and Strategy

Profitability

  • Margin improvement Profitability · FY26 · High confidence 150 bps
    We expect to see top line growth of 13% to 14% in FY '26 with around 150 bps margin improvement, which will happen over the course of the year.

    — Satish Mehta, MD & CEO

  • Long-term margin improvement Profitability · over 3-4 years · Medium confidence 300-400 bps
    I think in the past, we've also guided to over a 3- to 4-year period, probably a 300, 400 basis point sort of improvement in the margin profile of the business.

    — Vikas Thapar, President, Corporate Development, Strategy and Finance

Debt

  • Debt status Debt · end of financial year FY26 · High confidence debt-free
    Yes, we probably see being debt-free by the end of financial year FY'26.

    — Tajuddin Shaikh, CFO

Capex

  • Capex budget Capex · FY26 · High confidence INR 350 crores (range INR 25-50 crores)
    Yes. I think we've historically guided to probably in the range of about INR 350 crores. And I think we'll be somewhere in that range, give or take, INR 25-50 crores.

    — Vikas Thapar, President, Corporate Development, Strategy and Finance

What to watch in Q1 FY26

FY26 Top Line Growth

next quarter
Current FY25 Revenue growth 19%
Target 13-14% growth for FY26

Why it matters

To assess if the company is on track to meet its annual revenue growth guidance.

We expect to see top line growth of 13% to 14% in FY '26 with around 150 bps margin improvement, which will happen over the course of the year.

Risks & concerns

  • Product Mix Impact on Gross Margins

    medium

    Gross margins in Q4 FY25 were impacted by a higher proportion of lower-margin ARV and Sanofi products in the mix. Management expects new product launches to improve this.

    Management acknowledged

  • Speed of Regulatory Clearance for Semaglutide

    medium

    While Emcure is on track for trials for semaglutide, the speed of regulatory clearance is an uncontrollable factor that could affect launch timelines.

    Management acknowledged

Q&A highlights

8 direct
Margin Expansion Drivers for FY26 Direct
I think it's a combination of factors. Obviously, we have operating leverage as the business continues to scale, higher productivity from some of the recently hired field force and in particular some of the newer divisions. Of course, some of the restructuring we did vis-a-vis the cardio-diabeto division and the Sanofi portfolio along with our own cardio products will also lead to some ongoing synergies.

Management detailed the multi-faceted strategy for achieving the guided 150 bps margin improvement, including operational efficiencies, new product mix, and restructuring benefits.

Asked by Amlan Jyoti

Sanofi Business Performance Post-Restructuring Direct
So, in Sanofi, for a large period of time, they had not been spending promotional expenses on some of the legacy and key products like Cardace. And so, what we have done is we've taken a lot of our cardiologist KOLs and invested heavily in education activities, scientific meetings, which was not done for several years on Cardace.

Clarified the current sales run-rate for the acquired Sanofi portfolio (INR 440-450 crores in FY25) and outlined specific actions taken to revive growth, indicating confidence in future performance post-restructuring.

Asked by Alankar Garude

Q4 Gross Margin Decline and Product Mix Direct
So, if I can just chime in. So, year-over-year, I think it's about 250 basis points reduced GC compared to the prior year-over-year quarter. And like Piyush said, that's predominantly driven by the Sanofi and ARV component being relatively higher this year vis-a-vis last year. The base business gross margins are actually up slightly compared to prior year Q4.

Addressed the reasons for the lower gross margins in Q4 FY25, attributing it primarily to a less favorable product mix with higher contributions from lower-margin ARV and Sanofi businesses, and timing aspects of international sales.

Asked by Alankar Garude

Canada Sales Dip in Q4 Direct
Yes. So, Canada, I think we had mentioned last quarter also that last quarter was a bit heavy because there was some sales which got preponed booking. So that impacted in Q4. I think what you mentioned is, if you look at for the full year, the base business grew in mid- to high teens for us in FY '25.

Provided context for the sequential decline in Canada sales, explaining it was due to preponed bookings in the previous quarter, reassuring that the full-year performance remained strong.

Asked by Gagan

ADC (Antibody-Drug Conjugate) Strategy and Pipeline Direct
So, specifically talking about ADC, I think this is the first opportunity for us in terms of real collaboration between our biologics arm and the small molecules given that we started off with an antibody that will be made by Gennova and then have the linker and payload from the chemistry side.

Revealed Emcure's entry into the high-potential ADC space, outlining a collaborative, low-risk strategy leveraging internal capabilities and targeting global markets with novel IP.

Asked by Dhawal

Recombinant Asparaginase Market and Competition Direct
Not in the recombinant. Right now, at least from whatever publicly available data on SCC or CDS, still looks like on the recombinant, we are the only filers. Of course, globally, Spectrila is the brand, which is from Medac, Germany, and our bio studies have been performed against that product.

Highlighted Emcure's unique position as the sole filer for recombinant Asparaginase in India, addressing a critical need for a first-line treatment for Pediatric ALL with quality issues in existing natural products.

Asked by Girish Bakhru

Emcutix (Derma Subsidiary) Strategy and Portfolio Direct
No. This is a fledgling company. We started really the operations only in the month of January. but I must tell you that the Chief Executive that we have, he comes to us from great background. And to be honest with you, when I started this division, I didn't know that as far as derma market is concerned, it consists of so many things.

Provided insights into the new derma subsidiary, Emcutix, its recent launch, leadership, and broad focus beyond traditional derma to include cosmetology, geriatric, and anti-pollution segments, with a robust product pipeline.

Asked by Girish Bakhru

Long-term Margin Improvement Beyond FY26 Direct
I think in the past, we've also guided to over a 3- to 4-year period, probably a 300, 400 basis point sort of improvement in the margin profile of the business.

Confirmed management's long-term aspiration for significant margin expansion (300-400 bps over 3-4 years) beyond the FY26 target, reinforcing the strategic focus on profitability.

Asked by Bharat Shah

3 min read 7 chapters

Detailed narrative

Strong Financial Performance in Q4 and FY25

Emcure Pharmaceuticals reported robust financial results for Q4 FY25, with revenues growing 19.5% year-over-year to INR 2,116 crores. Domestic business saw a significant 25% growth, while international business grew 16%. For the full fiscal year 2025, the company achieved a top-line growth of 18.5% to INR 7,896 crores, with PAT increasing 34.1% to INR 707 crores. EBITDA margins for Q4 stood at 18.4%, supported by operating leverage despite lower gross margins of 57.8% due to product mix.

Strategic Portfolio Expansion in Domestic Market

FY25 was a transformational year for Emcure's domestic operations. The company successfully integrated the Sanofi cardio business into its portfolio, which contributed INR 440-450 crores in FY25 despite product shortages. Emcure sharpened its focus on the derma segment with the launch of its subsidiary, Emcutix, introducing differentiated products like PRX-PLUS and Flawzilo. The women's health portfolio was expanded, and the company entered the OTC segment with Arth and Galact brands, aiming for low double-digit growth in the domestic market for FY26.

Robust Growth and Key Approvals in International Markets

International markets demonstrated strong momentum, growing 16% in Q4 FY25 and 20% for the full year. Emerging Markets grew 27% in FY25, with expectations of closer to 20% growth in FY26. Canada outperformed with 35% growth in FY25, aided by the integration of the Mantra subsidiary. In the European Union, Emcure received approval for Amphotericin B Liposomal, marking it as the first generic to receive such approval in the EU, and also acquired Manx Healthcare's portfolio to expand its UK offerings.

FY26 Outlook and Margin Improvement Strategy

Emcure provided an optimistic outlook for FY26, guiding for a top-line growth of 13% to 14% and an improvement of approximately 150 basis points in margins. This improvement is expected to be driven by operating leverage, increased productivity from new field force, synergies from restructuring efforts, and a more favorable product mix from new launches. Management also expressed a long-term aspiration for 300-400 bps margin improvement over the next 3-4 years, emphasizing execution across all segments.

Capital Allocation and Debt Reduction

The company made significant strides in strengthening its balance sheet, reducing net debt to INR 488 crores in FY25 from INR 1,558 crores in FY24. Management aims to achieve a debt-free status by the end of FY26. Planned capital expenditure for FY26 is estimated to be around INR 350 crores. For shareholders, the board recommended a dividend of INR 3 per share for FY25.

Advanced Product Pipeline and R&D Focus

Emcure is actively developing a differentiated product pipeline. Its Gennova subsidiary has Bevacizumab for wAMD in Phase III, with a launch expected in FY26, marking its entry into the ophthalmic segment. The company has also filed for approval of R-Asparaginase in oncology, which will be the first time this recombinant product is available in India. Emcure is also on track to be in the first wave of launches post-expiry for semaglutide and is exploring complex injectables, biosimilars, new drug delivery routes, and ADC (Antibody-Drug Conjugates) through its Scientific Advisory Committee.

Derma and Women's Health Segment Focus

The newly launched derma subsidiary, Emcutix, which began operations in January, is focusing on a broad range of areas including cosmetology, geriatric care, and anti-pollution products. It currently has 8 brands with 6 more in the pipeline for the next 12 months. In women's health, Emcure launched new products for menopause and PCOS segments and plans further launches in FY26, aiming to address unmet needs and capitalize on the significant market potential for these rapidly growing areas.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls